Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody designed to combat Zaire ebolavirus by binding to its surface glycoprotein. This binding action inhibits the virus's entry into host cells, effectively exhibiting antiviral activity [1].